Empagliflozin, a sodium-glucose cotransporter 2 inhibitor that lowers blood glucose levels by increasing the amount excreted in urine, was recently approved by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in children 10 years or older. The drug—marketed as Jardiance when administered alone and as Synjardy when combined with metformin—has already been approved for adults with type 2 diabetes. It is taken by mouth and can be used in addition to dietary changes and exercise to improve blood glucose levels, the FDA said in a statement. The approval is based on results from a randomized clinical trial involving 158 participants.
Source: JAMA Online First